Previous 10 | Next 10 |
Our analysis concludes MEI Pharma Inc.'s (MEIP) recent sell-off is materially overdone. MEIP's sell-off is (most likely) due to a recent unexpected announcement of the discontinuation of MEIP's most clinically advanced oncology program (Pracinostat) in development by MEIP's licensee. However, ...
Gainers: Francesca's (NASDAQ: FRAN ) +68% . More news on: Francesca's Holdings Corporation, Electrameccanica Vehicles Corp., Interpace Biosciences, Inc., Stocks on the move, , Read more ...
Shares in MEI Pharma (NASDAQ: MEIP) are tumbling 15.3% at 11:55 a.m. EDT on Thursday following news its collaboration partner, Helsinn Group, is discontinuing a phase 3 trial of pracinostat in acute myeloid leukemia, or AML. Helsinn Group was studying pracinostat alongside Vidaza as a pot...
Sunworks (NASDAQ: SUNW ) -23% . More news on: Sunworks, Inc., Document Security Systems, Inc., Alterity Therapeutics Limited, Stocks on the move, , Read more ...
The following slide deck was published by MEI Pharma, Inc. in conjunction with this Read more ...
These Penny Stocks Just Hit New 52-Week Highs. Are They Still A Buy? There’s no getting around the fact that penny stocks are high-risk equities. Just as quickly as they move up, they can come crashing down. In line with this, there’ve been plenty of higher-priced stocks that r...
Sonoma Pharmaceuticals (NASDAQ: SNOA ) +162% on COVID-19 nod in Australia for disinfectant. More news on: Sonoma Pharmaceuticals, Inc., Phio Pharmaceuticals Corp., Adaptimmune Therapeutics plc, Stocks on the move, , Read more ...
It should first be noted we did not consult with Epizyme, Inc. in the preparation of this article. Our analysis concludes Epizyme, Inc.'s (EPZM) is an incredible company and EPZM's product Tazverik could have a bright future treating those who suffer from Follicular Lymphoma. EPZM's Tazverik...
SAN DIEGO , May 27, 2020 /PRNewswire/ -- MEI Pharma, Inc. (NASDAQ: MEIP) ("MEI"), a late-stage pharmaceutical company focused on advancing new therapies for cancer, today announced that Daniel P. Gold, Ph.D., president and chief executive officer of MEI, will present a company overvi...
SAN DIEGO , May 26, 2020 /PRNewswire/ -- MEI Pharma, Inc. (NASDAQ: MEIP) ("MEI"), a late-stage pharmaceutical company focused on advancing new therapies for cancer, today announced that it will host an investor and analyst video webcast event on Tuesday, June 2 nd , 2020 at 8:00 A...
News, Short Squeeze, Breakout and More Instantly...
-- Ongoing Phase 1 Study Evaluating Voruciclib Plus Venetoclax Demonstrates Anti-leukemic Activity, Including Complete Responses, Anticipated Decreases in Mcl-1 and No Overlapping Toxicity in Heavily Pretreated R/R AML Patients -- -- Board of Directors Unanimously Aligned on Prioritizatio...
– MEI Pharma Board Unanimously Determines, Based on Clinical Data Results, Not to Proceed with Second Capital Return Under 2023 Anson and Cable Car Cooperation Agreement: Conserving Capital, Prioritizing Measured Investment, Extending Operational Runway – MEI Pharma, Inc. ...